The drug is recommended in treating the disease, which affects the spine, in severe cases when used as directed for other tumour necrosis factor inhibitor treatments. MSD will also provide the drug at the same price for both 50mg and 100mg doses, meaning annual treatment costs are slightly over £9,000. NICE does not consider this an excessive price.
Ankylosing spondylitis has no known cause and can lead bones and joints to fuse together. Professor Carole Longson of NICE was pleased to recommend Simponi for “this progressive and irreversible condition.” MSD’s drug is more cost effective than the two current drugs used to treat the condition, so was appraised sooner than it may otherwise have been. The drug can only be taken if it is proved over a twelve week period the disease is active and conventional steroid treatment has failed.
CK Clinical, the leading independent pharmaceutical recruitmentconsultancy are recruiting for a Statistical Programmer for a leading CRO based in Wales.
This Statistical Programmer role will involve taking responsibility for the statistical analysis and reporting of a number of phase I clinical trials, providing input into clinical study protocols, writing statistical analysis plans, performing statistical analyses and reporting of TFLs to internal management and to external clients.
The main responsibilities of this Statistical Programmer role will include:
Providing statistical input into the planning and development of clinical study protocols by creating/adapting the appropriate statistical requirements.
Being involved in the creation of statistical analysis plans including the designing of data listings, table and figure shells for external clients in liaison with project managers.
Providing clinical SAS programming support to projects according to specifications within the statistical analysis plan.
We are interested in applicants that hold an MSc in Statistics with proven experience as a Statistician working for either a Pharmaceutical/CRO/Biotechnology organisation. The ideal candidate for this Statistical Programmer role will also have substantial SAS programming expertise in the BASE, STAT and GRAPH modules of SAS (v9.1.3) to create listings, tables and figures. Working within Phases I & II is also desirable.
For more information, or to apply for this Statistical Programmer online now, please contact Priya at CK Clinical on +44 (0) 1438 870028 or email an updated copy of your CV to: email@example.com.
As reported by the BBC News, Quay Pharma, a specialist in testing and designing new products for the pharmaceutical industry plans to create 65 new research and development jobs in Deeside, Wales.
A £2.7 million pharmaceutical facility will be created at the industrial park in Shotton. This will be opened by Deputy First Minister Ieuan Wyn Jones, who announced £784,000 in funding for the facility last year. Speaking of the new development Mr Jones stated: “I am therefore especially pleased that we have been able to offer assistance to the company to facilitate their expansion programme and I hope that their research and development funding will be of further assistance.”
Currently approximately, 15,000 people in Wales work in the healthcare and bioscience sector and the industry is worth £1.3 billion each year to Wales.
Quay Pharma was originally established in 2001 by Professor Mike Rubinstein, former director of the School of Pharmacy at Liverpool John Moores University, and Dave Patterson, a north Wales businessman who has had other pharmaceutical businesses in the area for the last 15 years.
The pharmaceutical company was originally based on the Wirral but expanded and moved its headquarters and manufacturing operations to the industrial park in Deeside in January 2010.